Outcomes of vascular closure devices for femoral venous hemostasis following catheter ablation of atrial fibrillation

Mark T. Mills,Peter Calvert,Gregory Y. H. Lip,Vishal Luther,Dhiraj Gupta
DOI: https://doi.org/10.1111/jce.16345
IF: 2.7
2024-06-26
Journal of Cardiovascular Electrophysiology
Abstract:Introduction Access site complications remain common following atrial fibrillation (AF) catheter ablation. Femoral vascular closure devices (VCDs) reduce time to hemostasis compared with manual compression, although large‐scale data comparing clinical outcomes between the two approaches are lacking. Methods Two cohorts of patients undergoing AF ablation were identified from 36 healthcare organizations using a global federated research network (TriNetX): those receiving a VCD for femoral hemostasis, and those not receiving a VCD. A 1:1 propensity score matching (PSM) model based on baseline characteristics was used to create two comparable cohorts. The primary outcome was a composite of all‐cause mortality, vascular complications, bleeding events, and need for blood transfusion. Outcomes were assessed during early (within 7 days of ablation) and extended follow‐up (within 8–30 days of ablation). Results After PSM, 28 872 patients were included (14 436 in each cohort). The primary composite outcome occurred less frequently in the VCD cohort during early (1.97% vs. 2.60%, odds ratio (OR) 0.76, 95% confidence interval (CI) 0.65–0.88; p
cardiac & cardiovascular systems
What problem does this paper attempt to address?